Virginia is currently home to 1836 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013
Recruiting
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). Approximately 1700 additional participants will be enrolled in an addendum to explore Lp(a) lowering with an alternative dosing schema.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Virginia Heart, Falls Church, Virginia
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Register for Updates
A Virtual Reality Brief Violence Intervention: Preventing Gun Violence Among Violently Injured Adults
NCT06239285
Recruiting
The overall aim of the proposed project is to develop and evaluate the effectiveness of Brief Violence Intervention-Virtual Reality (BVI-VR) for reducing firearm-related violence, re-injury, and mortality among victims of violence. Outcome measures of firearm-related violence will come from multiple sources, including criminal background checks, hospital data, state-level data, semi-structured clinical assessments, and self-report assessments. In addition, the study aims to understand the impact... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Violence
Register for Updates
Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1
NCT06204809
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of single intravenous (IV) doses of PGN-EDODM1 administered to participants with Myotonic Dystrophy Type 1 (DM1). The study consists of 2 periods: A Screening Period (up to 30 days) and a Treatment and Observation Period (16 weeks).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/06/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Myotonic Dystrophy 1
Register for Updates
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418
Recruiting
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
06/06/2025
Locations: Chippenham Johnston Willis Medical Center, Richmond, Virginia
Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Register for Updates
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728
Recruiting
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Research Site, Fairfax, Virginia
Conditions: Unresectable Pleural Mesothelioma
Register for Updates
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080
Recruiting
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/06/2025
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Large B-Cell Lymphoma
Register for Updates
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769
Recruiting
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
06/06/2025
Locations: University of Virginia Health System, Charlottesville, Virginia
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
LGMD R1 Natural History Study
NCT05618080
Recruiting
This is a 24-month, observational study of 100 participants with Limb Girdle Muscular Dystrophy type R1, also known as CAPN3.
Gender:
ALL
Ages:
Between 12 years and 50 years
Trial Updated:
06/06/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A, Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type R1, LGMD2A
Register for Updates
DMCRN-02-001: Assessing Pediatric Endpoints in DM1
NCT05224778
Recruiting
The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic dystrophy type 1 and develop biomarkers for the condition.
Gender:
ALL
Ages:
59 months and below
Trial Updated:
06/06/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Congenital Myotonic Dystrophy, CDM
Register for Updates
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
NCT05023486
Recruiting
Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Advanced or Metastatic Solid Tumor Malignancies
Register for Updates
Transforaminal Lumbar Interbody Fusion (TLIF)
NCT04073563
Recruiting
This is a global, multi-center, prospective, randomized, blinded, controlled pivotal study. Clinical and radiological evaluation will be performed preoperatively and postoperatively up to 24 months; and endpoint success will be determined at 24 months postoperatively. Overall a maximum of 600 subjects will be enrolled and treated. The purpose of the study is to provide safety and effectiveness data of Infuse™ in Transforaminal Lumbar Interbody Fusion (TLIF) procedures and to obtain indication e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University of Virginia - Clinical Trial Office, Charlottesville, Virginia
Conditions: Degenerative Disease of the Lumbosacral Spine
Register for Updates
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
NCT06983743
Recruiting
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/05/2025
Locations: NEXT Virginia, Fairfax, Virginia
Conditions: Metastatic Solid Tumors
Register for Updates